{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:01:25Z","timestamp":1790996485070,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40259-018-0311-4","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T09:42:16Z","timestamp":1538991736000},"page":"627-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn\u2019s Disease"],"prefix":"10.1007","volume":"32","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"issue":"11","key":"311_CR1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","volume":"14","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Rimola J. Perianal fistulizing Crohn\u2019s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(11):652\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"311_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/MIB.0000000000000315","volume":"21","author":"DA Schwartz","year":"2015","unstructured":"Schwartz DA, Ghazi LJ, Reguiero M, et al. Guidelines for the multidisciplinary management of Crohn\u2019s perianal fistulas: summary statement. Inflamm Bowel Dis. 2015;21(4):723\u201330.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"311_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","volume":"63","author":"KB Gecse","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease. Gut. 2014;63(9):1381\u201392.","journal-title":"Gut"},{"issue":"4","key":"311_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.gastro.2015.08.038","volume":"149","author":"D Garcia-Olmo","year":"2015","unstructured":"Garcia-Olmo D, Schwartz DA. Cumulative evidence that mesenchymal stem cells promote healing of perianal fistulas of patients with Crohn\u2019s disease: going from bench to bedside. Gastroenterology. 2015;149(4):853\u20137.","journal-title":"Gastroenterology"},{"issue":"10","key":"311_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/ecco-jcc\/jjx046","volume":"11","author":"AL Lightner","year":"2017","unstructured":"Lightner AL, Faubion WA. Mesenchymal stem cell injections for the treatment of perianal Crohn\u2019s disease: what we have accomplished and what we still need to do. J Crohns Colitis. 2017;11(10):1267\u201376.","journal-title":"J Crohns Colitis."},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1365-2036.2010.04439.x","volume":"32","author":"O Garcia-Bosch","year":"2010","unstructured":"Garcia-Bosch O, Ricart E, Pan\u00e9s J. Review article: stem cell therapies for inflammatory bowel disease - efficacy and safety. Aliment Pharmacol Ther. 2010;32:939\u201352.","journal-title":"Aliment Pharmacol Ther"},{"key":"311_CR7","unstructured":"European Medicines Agency. Orphan Maintenance Assessment Report. Alofisel (expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue): treatment of anal fistula 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 11 Sep 2018."},{"key":"311_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.gastro.2003.08.024","volume":"125","author":"American Gastroenterological Association Clinical Practice Committee","year":"2003","unstructured":"American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn\u2019s disease. Gastroenterology. 2003;125:1503\u20137.","journal-title":"Gastroenterology"},{"issue":"1","key":"311_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-017-0842-x","volume":"78","author":"F Bermejo","year":"2018","unstructured":"Bermejo F, Guerra I, Algaba A, et al. Pharmacological approach to the management of Crohn\u2019s disease patients with perianal disease. Drugs. 2018;78(1):1\u201318.","journal-title":"Drugs."},{"key":"311_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/187408","author":"I Molendijk","year":"2012","unstructured":"Molendijk I, Duijvestein M, van der Meulen-de Jong AE, et al. Immunomodulatory effects of mesenchymal stromal cells in Crohn\u2019s diease. J Allergy. 2012. \n                    https:\/\/doi.org\/10.1155\/2012\/187408\n                    \n                  .","journal-title":"J Allergy."},{"issue":"4","key":"311_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1586\/eci.10.27","volume":"24","author":"J Pan\u00e9s","year":"2010","unstructured":"Pan\u00e9s J, Ord\u00e1s I, Ricat E. Stem cell treatments for Crohn\u2019s disease. Expert Rev Clin Immunol. 2010;24(4):597\u2013605.","journal-title":"Expert Rev Clin Immunol."},{"issue":"10","key":"311_CR12","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1182\/blood-2007-02-069716","volume":"110","author":"AJ Nauta","year":"2007","unstructured":"Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499\u2013506.","journal-title":"Blood"},{"key":"311_CR13","unstructured":"TiGenix S. A. U. Alofisel (Darvadstrocel): summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 10 Sep 2018."},{"issue":"3","key":"311_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00384-012-1581-9","volume":"28","author":"F Portilla de la","year":"2013","unstructured":"de la Portilla F, Alba F, Garc\u00eda-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn\u2019s disease: results from a multicenter phase I\/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313\u201323.","journal-title":"Int J Colorectal Dis"},{"key":"311_CR15","unstructured":"EMA Committee for Advanced Therapies. Guidelines on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells (EMA\/CHMP\/410869\/2006). 2012. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 18 Sep 2018."},{"key":"311_CR16","unstructured":"EMA Committee for Advanced Therapies. Reflection paper on stem cell-based medicinal products. 2011. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 18 Sep 2018."},{"issue":"10051","key":"311_CR17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","volume":"388","author":"J Pan\u00e9s","year":"2016","unstructured":"Pan\u00e9s J, Garcia-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281\u201390.","journal-title":"Lancet"},{"issue":"7","key":"311_CR18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1136\/gut.2008.175067","volume":"58","author":"J Pan\u00e9s","year":"2009","unstructured":"Pan\u00e9s J, Salas A. Mechanisms underlying the beneficial effects of stem cell therapies for inflammatory bowel disease. Gut. 2009;58(7):898\u2013900.","journal-title":"Gut"},{"key":"311_CR19","unstructured":"Data on file, TiGenix S.A.U, 2018."},{"issue":"5","key":"311_CR20","doi-asserted-by":"publisher","first-page":"1334.e4","DOI":"10.1053\/j.gastro.2017.12.020","volume":"154","author":"J Pan\u00e9s","year":"2018","unstructured":"Pan\u00e9s J, Garc\u00eda-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2018;154(5):1334.e4\u201313342.e4.","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"311_CR21","doi-asserted-by":"publisher","first-page":"S408","DOI":"10.1093\/ecco-jcc\/jjx180.721","volume":"12","author":"J Pan\u00e9s","year":"2018","unstructured":"Pan\u00e9s J, Garc\u00eda-Olmo D, Parfionovas A, et al. Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn\u2019s disease (CD) [abstract no. P594]. J Crohn\u2019s Colitis. 2018;12(Suppl. 1):S408\u20139.","journal-title":"J Crohn\u2019s Colitis."},{"issue":"Suppl 1","key":"311_CR22","doi-asserted-by":"publisher","first-page":"S460","DOI":"10.1093\/ecco-jcc\/jjx180.818","volume":"12","author":"D Garc\u00eda-Olmo","year":"2018","unstructured":"Garc\u00eda-Olmo D, Pan\u00e9s J, Brayshaw N, et al. Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn\u2019s disease has rapid onset of clinical remission and low relapse rate by week 52 [abstract no. P691]. J Crohn\u2019s Colitis. 2018;12(Suppl 1):S460\u20131.","journal-title":"J Crohn\u2019s Colitis."},{"issue":"2","key":"311_CR23","first-page":"129","volume":"31","author":"SO Adegbola","year":"2018","unstructured":"Adegbola SO, Pisani A, Sahnan K, et al. Medical and surgical management of perianal Crohn\u2019s disease. Ann Gastroenterol. 2018;31(2):129\u201339.","journal-title":"Ann Gastroenterol."},{"issue":"4","key":"311_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/MIB.0000000000000377","volume":"21","author":"DA Schwartz","year":"2015","unstructured":"Schwartz DA, Ghazi LJ, Reguiero M. Guidelines for medical treatment of Crohn\u2019s perianal fistulas: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2015;21(4):737\u201352.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"311_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016. J Crohn\u2019s Colitis. Part 2: surgical management and special situations. 2017;11(2):135\u201349.","journal-title":"J Crohn\u2019s Colitis. Part 2: surgical management and special situations"},{"key":"311_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-018-3895-6","author":"T Georgiev-Hristov","year":"2018","unstructured":"Georgiev-Hristov T, Guadalajara H, Herreros MD, et al. A step-by-step surgical protocol for the treatment of perinanal fistula with adipose-derived mesenchymal stem cells. J Gastrointest Surg. 2018. \n                    https:\/\/doi.org\/10.1007\/s11605-018-3895-6\n                    \n                  .","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"311_CR27","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1097\/MEG.0000000000001208","volume":"30","author":"I Molendijk","year":"2018","unstructured":"Molendijk I, Van der Meulen-de Jong AE, Verspaget HW, et al. Standardization of mesenchymal stromal cell therapy for periananl fistulizing Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2018;30(10):1148\u201354.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"311_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex434","author":"M Jani","year":"2018","unstructured":"Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology. 2018. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kex434\n                    \n                  .","journal-title":"Rheumatology"},{"issue":"6","key":"311_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/1060028018754896","volume":"52","author":"SM McConachie","year":"2018","unstructured":"McConachie SM, Wilhelm SM, Bhargava A, et al. Biologic-induced infections in inflammatory bowel disease: the TNF-\u03b1 antagonists. Ann Pharmacother. 2018;52(6):571\u20139.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"311_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/DCR.0000000000001093","volume":"61","author":"AL Lightner","year":"2018","unstructured":"Lightner AL, Wang Z, Zubair AC, et al. A systematic review and meta-analysis of mesenchymal stem cell injections for the treatment of perianal Crohn\u2019s disease: progress made and future directions. Dis Colon Rectum. 2018;61(5):629\u201340.","journal-title":"Dis Colon Rectum"},{"issue":"6 Suppl 1","key":"311_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0016-5085(18)32704-5","volume":"154","author":"R Ciccocioppo","year":"2018","unstructured":"Ciccocioppo R, Klersy C, Leffler D, et al. Safety and efficacy of local injections of mesenchymal stem cells in perianal fistula in Crohn\u2019s disease: a systematic review and meta-analysis of the clinical trials and observational cohort studies [abstract no. Mo1653]. Gastroenterology. 2018;154(6 Suppl 1):784\u20135.","journal-title":"Gastroenterology."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0311-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T23:27:08Z","timestamp":1570490828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0311-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0311-4","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"8 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lesley Scott is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}